<DOC>
	<DOC>NCT00857311</DOC>
	<brief_summary>A Study to assess the general safety and tolerability of the administration of a 3-dose prime/boost regimen of the MRKAd5 HIV-1 gag vaccine (V520) in subjects with chronic hepatitis C virus infection.</brief_summary>
	<brief_title>MRKAd5 HIV-1 Gag Vaccine (V520) in Subjects With Chronic Hepatitis C (V520-022) (COMPLETED)</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subject who is of reproductive potential agrees to use a acceptable method of birth control through week 52 of the study Subject weighs less than 110 lbs. Subject has received treatment for hepatitis C virus infection in the 3 months before enrollment in this study or is anticipated to begin treatment with in 1 year after enrollment Subject has any history of anaphylaxis or allergy to vaccine components Subject has any history of anaphylaxis or allergy to Tetanus and Diphtheria Toxoids Adsorbed (Td) Subject has clinical signs suggestive of cirrhosis Subject has had a liver biopsy showing bridging fibrosis or cirrhosis Subject is HBsAg positive Subject has other known chronic liver disease Subject has evidence of hepatocellular carcinoma on liver biopsy Subject has had a liver transplant or is anticipated to have a liver transplant within 1 year of enrollment Subject has been vaccinated with a live virus vaccine in the past 30 days Subject has been vaccinated with an inactive virus vaccine in the past 14 days Female subject is pregnant or breastfeeding, Male subject is planning to impregnate Subject has active drug or alcohol abuse Subject is at high risk for HIV infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>